<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106908</url>
  </required_header>
  <id_info>
    <org_study_id>WIL-32</org_study_id>
    <nct_id>NCT04106908</nct_id>
  </id_info>
  <brief_title>Effectiveness and Tolerability of Eqwilate in Real-life Conditions</brief_title>
  <official_title>MOdalities of Use, effectiveNEss and TOlerability of Eqwilate® a Balanced combInatiON of VWF and FVIII in Von WillEbrand Patients in Real-life Conditions: the ONE-TO-ONE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MOdalities of use, effectiveNEss and TOlerability of Eqwilate® a balanced combInatiON of VWF
      and FVIII in von WillEbrand patients in real-life conditions: the ONE-TO-ONE study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Haemostatic Effectiveness of On-demand Treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Haemostatic Effectiveness of On-demand Treatment (excellent, good, moderate, none)
none: severe uncontrolled bleeding or intensity of bleeding not changed (in case of non-severe bleeding episodes); moderate: moderate bleeding, or control of bleeding required additional product; good: slight oozing and adequate control of bleeding episode and did not require additional product; excellent: haemostasis achieved, cessation of bleeding episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemostatic Effectiveness of Perioperative Prophylaxis</measure>
    <time_frame>12 months</time_frame>
    <description>Haemostatic Effectiveness of Perioperative Prophylaxis (excellent, good, moderate, none)
none: severe uncontrolled bleeding or intensity of bleeding not changed (in case of non-severe bleeding episodes); moderate: moderate bleeding, or control of bleeding required additional product; good: slight oozing and adequate control of bleeding episode and did not require additional product; excellent: haemostasis achieved, cessation of bleeding episode.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Bleeding Episodes During Follow-Up</measure>
    <time_frame>12 months</time_frame>
    <description>Occurrence of Bleeding Episodes During Follow-Up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FVIII Levels</measure>
    <time_frame>12 months</time_frame>
    <description>Clotting factor VII levels in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Productivity Loss</measure>
    <time_frame>12 months</time_frame>
    <description>Days lost from school or work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Blood loss</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Volume of Blood loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Presence of inhibitors against VWF</measure>
    <time_frame>12 months</time_frame>
    <description>Presence of inhibitors against VWF found via blood draw analysis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">47</enrollment>
  <condition>VWD - Von Willebrand's Disease</condition>
  <arm_group>
    <arm_group_label>Eqwilate</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eqwilate</intervention_name>
    <description>Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII</description>
    <arm_group_label>Eqwilate</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will involve patients (≥ 6 years of age) from the participating centres treated
        with Eqwilate® (either on-demand, as perioperative prophylaxis, or as prophylaxis) during
        the time inclusion period will be opened.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The study will involve patients (≥ 6 years of age) from the participating centres treated
        with Eqwilate® (either on-demand, as perioperative prophylaxis, or as prophylaxis) during
        the time inclusion period will be opened. Patients will be of any VWD type, previously
        treated or untreated.

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mikaela Raymond</last_name>
    <phone>866-337-1868</phone>
    <email>ctgov@clinicalresearchmgt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Caen Study Site</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clamart Study Site</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paris Study Site - Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paris Study Site - Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rennes Study Site</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rouen Study Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Denis Study Site - Pediatrie</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Denis Study Site</name>
      <address>
        <city>Saint-Denis</city>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne Study Site</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

